Based on the bradykinin hypothesis on the trigger of the cytokine storm in severe Covid-19 [12,13,14,15], these results suggest that the compound could be used for its treatment. Present results support previous claims suggesting the use of raloxifene based on its capacity to inhibit the IL-6/STAT3 signaling pathway [45], and also for being a prospective antiviral agent for SARS-Cov2 as inhibitor of the two-pore channel TCP2 [48]. Very recently a clinical trial in Italy has been approved to test its efficacy in COVID-19 patients with mild symptoms [50].